Patient-friendly summary
If you read nothing else
Bottom line
Pharmacological treatment is an essential but limited part of fibromyalgia care; antidepressants and anticonvulsants are favored, strong opioids discouraged, and outcomes are best when medication is personalized and combined with non-drug therapies.
Moderate evidencePublished
Evidence hierarchy
Study participants
Adults with fibromyalgia syndrome
Full research — for clinicians and curious readers
Study Summary
This practice-based narrative review summarizes the drugs used in everyday clinical practice to treat fibromyalgia syndrome (FMS), a chronic widespread-pain condition with fatigue, sleep disturbance, and mood symptoms. The authors note that only three drugs (pregabalin, duloxetine, and milnacipran) are FDA-approved for FMS, none are EMA-approved, and most medications offer limited benefit, often addressing only some symptom domains or having modest effects on pain. They emphasize a "start low, go slow" approach within a multidisciplinary, bio-psychosocial framework, generally favoring antidepressants and anticonvulsants while discouraging strong opioids. The review argues that dividing patients into clinical subpopulations (for example, FMS with comorbid depression) and tailoring drug choice to individual symptoms may improve outcomes.
Key Findings
| Finding | Detail | Impact |
|---|---|---|
| Only three drugs are FDA-approved for fibromyalgia, and none are EMA-approved | Pregabalin, duloxetine, and milnacipran are FDA-approved for FMS; in Europe all drug use for FMS is off-label since no agents are EMA-approved. | High |
| Effective FMS drugs mainly act on the central nervous system, while NSAIDs and simple analgesics are reported as ineffective | Antidepressants (SNRIs, TCAs) and anticonvulsants (pregabalin, gabapentin) that target the CNS show the most promise; NSAIDs and analgesics have proven ineffective and tricyclics have limited effects, consistent with the nociplastic origin of FMS pain. | High |
| SNRIs are the most-used drugs but their efficacy is moderate | A cited meta-analysis reported that 42% of SNRI-treated patients achieved a 30% pain reduction versus 32% on placebo; duloxetine appears most effective when FMS is comorbid with depression, with a 120 mg/day dose improving pain and depression but causing more side effects. | High |
| Treatment benefits are often statistically significant but below clinically important thresholds | The review notes that improvements in quality of life from antidepressants and CNS depressants, while statistically significant, do not exceed the minimum clinically important change of 14 points on a 101-point scale, and evidence for long-term outcomes is insufficient. | High |
| Strong opioids should generally be avoided, while tramadol and tapentadol are possible exceptions | Opioids carry risks of tolerance, dependency, opioid-induced hyperalgesia, endocrine changes, and higher 10-year all-cause mortality; weak opioid tramadol showed efficacy in four RCTs (low-quality evidence) and is suggested as a 'SOS'/emergency option, with cannabinoids preferred over opioids. | Medium |
| Patient subgrouping and personalized therapy are recommended | The authors suggest dividing patients into clinical subpopulations such as FMS with comorbid depression, and note that gene-polymorphism studies of serotonergic and dopaminergic receptors may eventually enable genotype-based prescribing. | Medium |
Strengths
- Comprehensive, clinically oriented coverage spanning antidepressants, anticonvulsants, NMDA antagonists, myorelaxants, analgesics, opioids, GABAergic drugs, antipsychotics, and cannabinoids
- Provides practical dosing guidance (initial and target doses) and a 'start low, go slow' framework useful at the point of care
- Mirrors the evidence's own hedging, repeatedly noting limited efficacy, low certainty, and industry ties in the underlying trials
- Emphasizes personalized, subgroup-based and multidisciplinary treatment rather than a one-size-fits-all approach
Limitations
- Narrative (not systematic) review, so it carries a risk of selection bias and does not pool data with predefined methods
- Underlying evidence base is largely low-to-moderate certainty, with several older or small trials and noted industry funding
- Many efficacy claims rest on cited secondary sources rather than primary analysis by the authors
- Improvements reported for several drugs are statistically significant but may fall below clinically meaningful thresholds, and long-term outcome data are insufficient
Key Takeaways for Patients
What This Means for You
No medication cures fibromyalgia; current drugs tend to ease only some symptoms or provide modest pain relief, so they work best alongside non-drug therapies like exercise and cognitive-behavioral therapy.
Only pregabalin, duloxetine, and milnacipran are FDA-approved for fibromyalgia; many other drugs used are technically off-label, and none are approved by Europe's EMA.
Doctors are advised to 'start low and go slow,' adjusting medication gradually and matching the drug to your specific symptoms (for example, antidepressants when depression coexists).
Standard painkillers and anti-inflammatories (NSAIDs) are reported to be ineffective for fibromyalgia, and strong opioids are generally discouraged because of risks like dependence and worsening pain sensitivity.
Because fibromyalgia varies so much from person to person, treatment should be personalized, and combining medications with physical and psychological care gives the best chance of relief.
Read the Full Paper
Access the complete peer-reviewed study from Current Pain and Headache Reports